Form 4: Cytokinetics EVP Fady Ibraham Malik Sells Shares to Cover Restricted Stock Unit Vesting
SEC Form 4 Filing
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc, sold 2,449 shares of common stock on March 3, 2025, to cover a transaction related to the vesting of restricted stock units.
Summary
- On March 3, 2025, Fady Ibraham Malik, the EVP of Research & Development at Cytokinetics Inc., sold 2,449 shares of the company's common stock.
- The sale was executed at a price of $42.88 per share.
- The transaction was conducted to cover obligations related to the vesting of restricted stock units.
- Following the reported transaction, Malik directly owns 113,622 shares of Cytokinetics Inc.
Sentiment
Score: 5
Explanation: This is a neutral event. An executive selling shares to cover vesting obligations is a normal part of executive compensation and doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
This is a routine Form 4 filing, indicating a transaction by a company insider. Such filings are common and provide transparency into the trading activities of company executives.
Stakeholder Impact
- The sale has a minimal impact on shareholders as it is a small transaction by an individual executive.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of the stock sale transaction. |
| 03/05/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.